Yes, GLP-1 medications commonly cause changes in bowel movements, though the nature and severity of these changes vary significantly among patients
In 2025, the company delivered a solid +11.81% YoY revenue growth, largely driven by its vaccines portfolio: Shingrix ($4.85B) continues to lead with strong global uptake in shingles prevention, Bexsero ($1.61B) is gaining traction amid rising meningitis awareness and immunization programs, while Boostrix ($882.31M) remains a steady contributor in adult and adolescent vaccination, highlighting the strength of GSKs vaccines-led growth strategy
Many side effects are mild, especially during dose increases, but some symptoms should not be ignored
By route of administration analysis The parenteral segment was dominant in the global GLP-1 receptor agonist market in 2024
Gastrointestinal effects The most common consequence of early dosing is an increase in GI side effects
Some patients find that evening dosing helps manage daytime nausea, whilst others prefer morning administration to monitor symptoms throughout the day